TWD
ACTU

True Wealth Design’s Actuate Therapeutics ACTU Stock Holding History

True Wealth Design’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45 Buy
29
+15
+107% +$35 ﹤0.01% 2602
2026
Q1 		$39 Buy
14
+13
+1,300% +$54 ﹤0.01% 2583
2025
Q4 		$7 Buy
+1
New +$7 ﹤0.01% 2542

Other funds holding ACTU

GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return
GRWP
Green Ridge Wealth Planning Montville, New Jersey $238M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

True Wealth Design's ACTU Position: Q2 2026 in Review

True Wealth Design increased its Actuate Therapeutics (ACTU) stake by 107% in Q2 2026, buying an estimated $35 and bringing the position to 29 shares worth $45. The position accounts for ﹤0.01% of the portfolio, ranked #2602.

True Wealth Design first reported a position in ACTU in Q4 2025 and has held it in 3 quarters since. 5 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • True Wealth Design held 29 shares of Actuate Therapeutics worth $45 as of Q2 2026.
  • True Wealth Design bought 15 Actuate Therapeutics shares in Q2 2026, an estimated $35.
  • Actuate Therapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #2602 holding.
  • True Wealth Design first reported a position in Actuate Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 5 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.